Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243695868> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4243695868 endingPage "3057" @default.
- W4243695868 startingPage "3057" @default.
- W4243695868 abstract "3057 Background: CI-1033 is a pan-erbB tyrosine kinase inhibitor. In phase 1 oral (PO) studies, dose limiting toxicities were primarily gastrointestinal (GI), which supported the exploration of IV dosing to achieve higher drug exposures. Methods: Forty-eight patients (pts) with advanced nonhematologic malignancies received IV CI-1033 via 30 min infusions (10–500 mg) on a 3-day weekly (MWF) schedule. PK samples were collected on Days 1 and 8 and evaluated using compartmental analysis (NONMEM ADVAN3). Results: 28M/20F, ECOG PS 0 & 1, median age 54 (42–73), tumors: lung 11, colorectal 10, mesothelioma 9, melanoma 4, unknown primary 2, others 12. Despite a 5 to 10-fold increase in IV Cmax and a 3-fold increase in AUC compared to PO at equivalent doses, treatment-related GI AEs were notably less frequent with this IV regimen than with once weekly dosing of PO CI-1033 (100–1000 mg; n=55; Proc. ASCO 2001,283:72a). The incidences of the most common GI AEs when given IV were Gr 1–2 nausea (15%), vomiting (11%), diarrhea (7%) vs 60%, 40%, and 49%, respectively, with PO dosing. Whereas Gr 3 GI AEs occurred in 2% of pts on the PO study, none were reported in the IV study to date. The incidences of Gr 3 hypersensitivity were comparable for IV and PO regimens (each 2%). Systemic exposure was dose proportional with bi-phasic elimination. The initial distribution phase had a 2 to 3 minute half-life while the terminal elimination phase half-life was approx 3 hrs. Central volume of distribution (18.5 liters) approximated extravascular water volume. Systemic clearance was rapid at 3 L/min. Systemic exposure was not dependent upon age, gender, race, renal function, body weight or surface area in this IV study. Conclusions: Gastrointestinal AEs were less frequent following IV dosing relative to PO dosing at comparable systemic exposures and hence higher drug exposures could be acheived by the IV route. Oral bioavailability of CI-1033 is about one-third that observed following IV dosing. The clinical significance of the higher drug exposures achieved by the IV route is yet to be determined but warrants further investgation. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Pfizer Pfizer Pfizer" @default.
- W4243695868 created "2022-05-12" @default.
- W4243695868 creator A5004546542 @default.
- W4243695868 creator A5024946496 @default.
- W4243695868 creator A5039144013 @default.
- W4243695868 creator A5041062966 @default.
- W4243695868 creator A5048726993 @default.
- W4243695868 creator A5049076838 @default.
- W4243695868 creator A5057204740 @default.
- W4243695868 creator A5060651469 @default.
- W4243695868 creator A5090398875 @default.
- W4243695868 creator A5091318366 @default.
- W4243695868 date "2004-07-15" @default.
- W4243695868 modified "2023-10-14" @default.
- W4243695868 title "Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors" @default.
- W4243695868 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.3057" @default.
- W4243695868 hasPublicationYear "2004" @default.
- W4243695868 type Work @default.
- W4243695868 citedByCount "3" @default.
- W4243695868 crossrefType "journal-article" @default.
- W4243695868 hasAuthorship W4243695868A5004546542 @default.
- W4243695868 hasAuthorship W4243695868A5024946496 @default.
- W4243695868 hasAuthorship W4243695868A5039144013 @default.
- W4243695868 hasAuthorship W4243695868A5041062966 @default.
- W4243695868 hasAuthorship W4243695868A5048726993 @default.
- W4243695868 hasAuthorship W4243695868A5049076838 @default.
- W4243695868 hasAuthorship W4243695868A5057204740 @default.
- W4243695868 hasAuthorship W4243695868A5060651469 @default.
- W4243695868 hasAuthorship W4243695868A5090398875 @default.
- W4243695868 hasAuthorship W4243695868A5091318366 @default.
- W4243695868 hasConcept C112705442 @default.
- W4243695868 hasConcept C126322002 @default.
- W4243695868 hasConcept C22979827 @default.
- W4243695868 hasConcept C2777288759 @default.
- W4243695868 hasConcept C2778496288 @default.
- W4243695868 hasConcept C2780580376 @default.
- W4243695868 hasConcept C2780852908 @default.
- W4243695868 hasConcept C2781413609 @default.
- W4243695868 hasConcept C29730261 @default.
- W4243695868 hasConcept C71924100 @default.
- W4243695868 hasConcept C90924648 @default.
- W4243695868 hasConceptScore W4243695868C112705442 @default.
- W4243695868 hasConceptScore W4243695868C126322002 @default.
- W4243695868 hasConceptScore W4243695868C22979827 @default.
- W4243695868 hasConceptScore W4243695868C2777288759 @default.
- W4243695868 hasConceptScore W4243695868C2778496288 @default.
- W4243695868 hasConceptScore W4243695868C2780580376 @default.
- W4243695868 hasConceptScore W4243695868C2780852908 @default.
- W4243695868 hasConceptScore W4243695868C2781413609 @default.
- W4243695868 hasConceptScore W4243695868C29730261 @default.
- W4243695868 hasConceptScore W4243695868C71924100 @default.
- W4243695868 hasConceptScore W4243695868C90924648 @default.
- W4243695868 hasIssue "14_suppl" @default.
- W4243695868 hasLocation W42436958681 @default.
- W4243695868 hasOpenAccess W4243695868 @default.
- W4243695868 hasPrimaryLocation W42436958681 @default.
- W4243695868 hasRelatedWork W1992189987 @default.
- W4243695868 hasRelatedWork W2074629895 @default.
- W4243695868 hasRelatedWork W2151288869 @default.
- W4243695868 hasRelatedWork W2373159162 @default.
- W4243695868 hasRelatedWork W2375012438 @default.
- W4243695868 hasRelatedWork W2382265168 @default.
- W4243695868 hasRelatedWork W2385131479 @default.
- W4243695868 hasRelatedWork W2414579301 @default.
- W4243695868 hasRelatedWork W2417803418 @default.
- W4243695868 hasRelatedWork W3151787567 @default.
- W4243695868 hasVolume "22" @default.
- W4243695868 isParatext "false" @default.
- W4243695868 isRetracted "false" @default.
- W4243695868 workType "article" @default.